TP53 mutation detected in circulating exosomal DNA is associated with prognosis of patients with hepatocellular carcinoma

Figures & data

Table 1. Clinical characteristics of patients in this study.

Clinical Characteristics	N = 60 (%)
Gender
Female	20(33.3)
Male	40(66.7)
TP53 mutation
Positive	48(80.0)
Negative	12(20.0)
HBV
Positive	58(96.7)
Negative	2(3.3)
Cirrhosis
Positive	33(55.0)
Negative	27(45.0)
Preoperative AFP(ng/ml)
<400	20(33.3)
≥400	40(66.7)
Tumor thrombus
Positive	8(13.3)
Negative	52(86.7)
Microvascular invasion
Positive	27(45.0)
Negative	33(55.0)
Satellite nodules
Positive	19(31.7)
Negative	41(68.3)
Postoperation TACE
Executed	39(65.0)
Non-executed	21(35.0)

Abbreviations: TP53 mutation, tumor protein p53 mutation status in circulating Exosomal DNA; HBV, hepatitis B virus; AFP, alpha-fetoprotein.

Table 2. Results of correlation multivariate regression analysis between patient characteristics and MVI.

patient characteristics	Odds Ratio	95%CI		P
		Lower	Upper
intercept	0.73	0.00	448.02	0.93
TP53 mutations	1.07	1.02	1.13	<0.01
Age	0.85	0.76	0.96	<0.01
AFP	28.59	1.32	620.94	0.03
Satellite nodules	2.50	0.23	26.78	0.672
Cancer embolus	6.30	0.11	376.89	0.38
Sex	10.75	0.64	179.42	0.10
Size	1.37	0.94	2.00	0.10

Abbreviations: MVI: microvascular invasion; AFP: alpha-fetoprotein;

Figure 1. Long-term survival outcomes in HCC using Kaplan-Meier’s analysis:A. Survival time of mutation frequency in HCC. The results shown that the patients with MD/TD≥67 had shorter median survival time; B. MVI positive shown worse survival time; C. Tumor size >5 cm had worse result shorter survival time; D. Patient had not been postoperative tace had worse median survival than patients without satellite nodules. P value was assessed using the log-rank test.

Figure 2. Long-term survival outcomes in HCC with mutation frequency using Kaplan-Meier’s analysis:A. Survival curve of mutation frequency in patients with AFP<400. The results shown that the patients with MD/TD≥67 had worse survival time; B. Survival curve of mutation frequency in patients with Tumor thrombus. The results shown that the patients with MD/TD≥67 had worse median survival time; C. Survival curve of mutation frequency in patients without liver cirrhosis. The results shown that patients with MD/TD≥67 had worse median survival time; D. Survival curve of mutation frequency in patients who treated by Post-operation TACE. The results shown that patients with high MD/TD had worse survival time; E. Survival curve of mutation frequency in patients with Single lesion. The results shown that MD/TD≥67 result had worse median survival time. P value was assessed using the log-rank test.

Table 3. Multivariate Cox’s Proportional Hazards Model Assessing Factors Associated with RFS.

Risks Factors	HR*	95%CI		P Vaule
		Lower	Upper
Mutation frequency (MD/TD)
<67	Referent
≥67	4.61	1.70	12.48	0.003
Microvascular invasion
(-)	Referent
(+)	4.95	1.91	12.87	0.001
Size(cm)
<5 cm	Referent
≥5 cm	5.67	2.05	15.63	0.001
postoperation tace
(-)	Referent
(+)	0.42	0.21	0.86	0.018

*HRs greater than 1.0 indicates a higher risk of death

Table 4. Multivariate Cox’s Proportional Hazards Model Assessing Mutation frequency Associated with RFS in different Clinical characteristics.

status	Risks Factors(MD/TD)		HR*	95%CI		P Vaule
				Lower	Upper
Preoperative AFP<400ng/L		<67	Referent
		≥67	10.60	3.05	36.87	<0.001
No liver cirrhosis		<67	Referent
		≥67	27.91	4.86	160.37	<0.001
No cancer embolus		<67	Referent
		≥67	10.46	4.08	26.86	<0.001
Tumor number = 1		<67	Referent
		≥67	9.51	3.83	23.57	<0.001
postoperation tace		<67	Referent
		≥67	9.44	3.03	29.41	<0.001

Abbreviations: *HRs greater than 1.0 indicates a higher risk of death